Esperion Therapeutics Inc. (NASDAQ:ESPR) was downgraded by equities research analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued on Monday.

Several other research firms have also recently weighed in on ESPR. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 10th. JMP Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Sunday, November 6th. Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price objective (down from $64.00) on shares of Esperion Therapeutics in a research report on Saturday, October 15th. Chardan Capital reiterated a “neutral” rating and set a $12.50 price objective on shares of Esperion Therapeutics in a research report on Saturday, October 15th. Finally, Credit Suisse Group AG increased their price objective on shares of Esperion Therapeutics from $10.00 to $14.00 and gave the stock an “underperform” rating in a research report on Friday, October 14th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. Esperion Therapeutics has an average rating of “Hold” and a consensus target price of $23.39.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 11.00 on Monday. The firm’s 50-day moving average is $12.02 and its 200 day moving average is $12.81. The company’s market capitalization is $248.08 million. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $30.41.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.05. During the same quarter last year, the firm earned ($0.57) earnings per share. Equities research analysts predict that Esperion Therapeutics will post ($3.42) EPS for the current year.

In other Esperion Therapeutics news, COO Narendra D. Lalwani acquired 5,000 shares of the company’s stock in a transaction on Tuesday, November 1st. The shares were purchased at an average cost of $9.93 per share, with a total value of $49,650.00. Following the completion of the purchase, the chief operating officer now owns 5,000 shares of the company’s stock, valued at $49,650. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 35.40% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Pentwater Capital Management LP raised its position in Esperion Therapeutics by 6.6% in the second quarter. Pentwater Capital Management LP now owns 1,518,000 shares of the biopharmaceutical company’s stock worth $14,998,000 after buying an additional 94,000 shares during the period. BB Biotech AG raised its position in Esperion Therapeutics by 29.7% in the third quarter. BB Biotech AG now owns 1,308,542 shares of the biopharmaceutical company’s stock worth $18,123,000 after buying an additional 300,000 shares during the last quarter. Vanguard Group Inc. raised its position in Esperion Therapeutics by 10.2% in the second quarter. Vanguard Group Inc. now owns 811,704 shares of the biopharmaceutical company’s stock worth $8,020,000 after buying an additional 74,928 shares during the last quarter. BlackRock Fund Advisors raised its position in Esperion Therapeutics by 6.2% in the third quarter. BlackRock Fund Advisors now owns 698,775 shares of the biopharmaceutical company’s stock worth $9,678,000 after buying an additional 40,856 shares during the last quarter. Finally, BVF Inc. IL purchased a new position in Esperion Therapeutics during the first quarter worth $10,261,000. 64.21% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.